At a glance
What is this study about?
A significant proportion of patients who undergo liver surgery to remove bowel cancer that has spread to the liver (metastases) develop disease recurrence and die from the disease. A previous small study (the EMT study) suggested a possible survival benefit in patients who took the naturally-occurring omega-3 fatty acid EPA (a fish oil supplement) before liver surgery. The EMT2 study is a larger study which will recruit 448 men and women with liver metastases from bowel cancer. Trial participants will receive either Icosapent Ethyl (pure EPA derived from fish oil) or placebo (dummy capsules). EMT2 will investigate whether patients who take this supplement before liver surgery and for up to four years after surgery, remain free of recurrence for longer than those who take placebo (dummy capsules)
Who may be eligible?
Age 18 Years to any · Sex: ALL
Locations (13)
- Oxford University Hospital NHS Foundation TrustOxford, United Kingdom
- Hampshire Hospitals NHS Foundation TrustBasingstoke, United Kingdom
- Aintree University Hospitals NHS Foundation TrustAintree, United Kingdom
- University Hospitals Birmingham NHS Foundation TrustBirmingham, United Kingdom
- Cambridge UniversityHospitals NHS Foundation TrustCambridge, United Kingdom
- University Hospital of WalesCardiff, United Kingdom
- Leeds Teaching Hospitals NHS Foundation TrustLeeds, United Kingdom
- King's College LondonLondon, United Kingdom
- Royal Free London NHS Foundation TrustLondon, United Kingdom
- Newcastle Upon Tyne Hospitals NHS Foundation TrustNewcastle, United Kingdom
- Nottingham University Hospitals NHS TrustNottingham, United Kingdom
- Sheffield Teaching Hospitals NHS Foundation TrustSheffield, United Kingdom
+1 more sites — see the official record for the full list.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.